Furthermore, we demonstrated that PINX1 deficiency leads to susceptibility of cancer cells to PARP inhibitors both in vitro and in vivo, suggesting that its inhibition combined with PARP inhibitors can serve as a potential therapeutic strategy. This evidence concerns the gene PINX1 and cancer.